Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (1-10 of 348) with videos related to

Pageof 35
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2008
Structures of PD-1 with its ligands: sideways and dancing cheek to cheekGordon J Freeman
Cancer Discovery|January 14, 2015
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapyYanping Xiao, Gordon J Freeman
Immunological Reviews|May 12, 2009
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activationGuifang Cai, Gordon J Freeman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2Yanping Xiao, Gordon J Freeman
Nature Immunology|December 12, 2019
Acidity changes immunology: a new VISTA pathwayKathleen M Mahoney, Gordon J Freeman
Immunity|July 2, 2013
Costimulatory genes: hotspots of conflict between host defense and autoimmunityJennifer C Jones, Gordon J Freeman
Nature Immunology|January 21, 2012
A new therapeutic strategy for malaria: targeting T cell exhaustionGordon J Freeman, Arlene H Sharpe
Nature Reviews. Immunology|March 26, 2002
The B7-CD28 superfamilyArlene H Sharpe, Gordon J Freeman
Cancer Research|August 27, 2013
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerJaikumar Duraiswamy, Gordon J Freeman, George Coukos
Cancer Research|January 11, 2014
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--responseJaikumar Duraiswamy, Gordon J Freeman, George Coukos
Pageof 35

Showing results (1-10 of 348) with videos related to

Sort By:
Pageof 35
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2008
Structures of PD-1 with its ligands: sideways and dancing cheek to cheekGordon J Freeman
Cancer Discovery|January 14, 2015
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapyYanping Xiao, Gordon J Freeman
Immunological Reviews|May 12, 2009
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activationGuifang Cai, Gordon J Freeman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2Yanping Xiao, Gordon J Freeman
Nature Immunology|December 12, 2019
Acidity changes immunology: a new VISTA pathwayKathleen M Mahoney, Gordon J Freeman
Immunity|July 2, 2013
Costimulatory genes: hotspots of conflict between host defense and autoimmunityJennifer C Jones, Gordon J Freeman
Nature Immunology|January 21, 2012
A new therapeutic strategy for malaria: targeting T cell exhaustionGordon J Freeman, Arlene H Sharpe
Nature Reviews. Immunology|March 26, 2002
The B7-CD28 superfamilyArlene H Sharpe, Gordon J Freeman
Cancer Research|August 27, 2013
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerJaikumar Duraiswamy, Gordon J Freeman, George Coukos
Cancer Research|January 11, 2014
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--responseJaikumar Duraiswamy, Gordon J Freeman, George Coukos
Pageof 35